

Global Genitourinary Drugs Market Size study, by Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), by Product (Hormonal Therapy, Gynecological), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GA8007E67409EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: GA8007E67409EN

Abstracts

The Global Genitourinary Drugs Market is valued at approximately USD 29.32 billion in 2023 and is projected to grow at a moderate CAGR of more than 1.10% during the forecast period 2024–2032. As genitourinary diseases continue to exert a significant toll on public health across the globe, the market for therapeutic solutions aimed at addressing these ailments is expanding with cautious optimism. Genitourinary drugs encompass treatments for a broad spectrum of indications ranging from urinary tract infections (UTIs) and sexually transmitted diseases (STDs) to complex cancers such as bladder, prostate, ovarian, and cervical malignancies. The gradual demographic shift towards an aging population, along with improved access to gynecological care, has positioned hormonal and gynecological therapies at the forefront of this evolving market.

An uptick in cancer screening programs, particularly in developed economies, is enabling earlier diagnosis and subsequently elevating the demand for effective first-line and adjuvant therapies. Hormonal treatment regimens, especially for hormone-responsive ovarian and prostate cancers, are gaining increased adoption. Moreover, the advancement of personalized medicine and molecular-targeted drug development is augmenting the efficacy of treatment options across various tumor types and infectious conditions. However, the market's progression is hampered by pricing pressures, low awareness in low-income nations, and regulatory delays for newer class approvals. These barriers are compelling industry players to recalibrate strategies through pipeline diversification and lifecycle management of existing blockbusters.

The market is undergoing a tactical transformation driven by an increase in outpatient

drug prescriptions and telehealth-enabled urology services, both of which are expanding patient reach. Key players are investing in the development of once-daily oral formulations and combination therapies aimed at boosting compliance and clinical outcomes. Furthermore, collaborations with academic institutions and public health agencies are on the rise to advance research on neglected genitourinary infections. With the support of AI-backed diagnostics and precision drug matching, the sector is slowly but steadily shifting from empirical treatments to tailored interventions, especially in oncological indications that were once hard to target effectively.

Geographically, North America leads the global genitourinary drugs market, bolstered by its advanced urological care ecosystem, high healthcare spending, and the availability of branded specialty drugs. The U.S. plays a pivotal role with its robust reimbursement framework and continuous innovation in hormonal and immune-modulating therapies. Europe follows closely with a comprehensive policy approach towards women's health, preventive cancer care, and subsidized prescription plans across member countries. Meanwhile, the Asia Pacific region is emerging as a promising frontier, driven by an increasing prevalence of genitourinary disorders, better screening coverage, and government support for generic drug penetration in populous nations such as India and China.

Major market player included in this report are:

Pfizer Inc.

Bayer AG

Astellas Pharma Inc.

GlaxoSmithKline plc

Johnson & Johnson

Novartis AG

F. Hoffmann-La Roche Ltd.

Merck & Co., Inc.

Sanofi S.A.

AbbVie Inc.

AstraZeneca

Bristol-Myers Squibb Company

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Dr. Reddy's Laboratories Ltd.

The detailed segments and sub-segment of the market are explained below:

By Indication

Prostate Cancer

Ovarian Cancer

Bladder Cancer

Cervical Cancer

Urinary Tract Infections (UTI)

Sexually Transmitted Diseases (STD)

By Product

Hormonal Therapy

Gynecological

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL GENITOURINARY DRUGS MARKET EXECUTIVE SUMMARY

- 1.1. Global Genitourinary Drugs Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Indication
 - 1.3.2. By Product
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL GENITOURINARY DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Patient Awareness & Screening Practices
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL GENITOURINARY DRUGS MARKET DYNAMICS

- 3.1. Market Drivers

- 3.1.1. Growing Burden of Genitourinary Cancers and Infections
- 3.1.2. Advancements in Hormonal and Targeted Therapies
- 3.1.3. Expansion of Screening and Early Diagnosis Programs
- 3.2. Market Challenges
 - 3.2.1. Pricing Pressures and Reimbursement Hurdles
 - 3.2.2. Limited Access in Emerging Economies
 - 3.2.3. Regulatory Delays for Novel Drug Approvals
- 3.3. Market Opportunities
 - 3.3.1. Lifecycle Management of Legacy Blockbusters
 - 3.3.2. Growth of Telehealth-Enabled Urology Services
 - 3.3.3. Adoption of Personalized Medicine and Biomarker-Guided Treatments

CHAPTER 4. GLOBAL GENITOURINARY DRUGS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
 - 4.1.6. Futuristic Approach to Porter's 5 Force Model
 - 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economical
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
 - 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE & FORECASTS BY INDICATION 2022–2032

5.1. Segment Dashboard

Global Genitourinary Drugs Market Size study, by Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI...

5.2. Genitourinary Drugs Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 5.2.1. Prostate Cancer
- 5.2.2. Ovarian Cancer
- 5.2.3. Bladder Cancer
- 5.2.4. Cervical Cancer
- 5.2.5. Urinary Tract Infections (UTI)
- 5.2.6. Sexually Transmitted Diseases (STD)

CHAPTER 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE & FORECASTS BY PRODUCT 2022–2032

6.1. Segment Dashboard

6.2. Genitourinary Drugs Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)

- 6.2.1. Hormonal Therapy
- 6.2.2. Gynecological

CHAPTER 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE & FORECASTS BY REGION 2022–2032

7.1. North America Market

- 7.1.1. U.S. Market
 - 7.1.1.1. Indication Breakdown Size & Forecasts, 2022–2032
 - 7.1.1.2. Product Breakdown Size & Forecasts, 2022–2032
- 7.1.2. Canada Market

7.2. Europe Market

- 7.2.1. UK Market
- 7.2.2. Germany Market
- 7.2.3. France Market
- 7.2.4. Spain Market
- 7.2.5. Italy Market
- 7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market

- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Pfizer Inc.
 - 8.1.2. Bayer AG
 - 8.1.3. Astellas Pharma Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Pfizer Inc.
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Bayer AG
 - 8.3.3. Astellas Pharma Inc.
 - 8.3.4. GlaxoSmithKline plc
 - 8.3.5. Johnson & Johnson
 - 8.3.6. Novartis AG
 - 8.3.7. F. Hoffmann-La Roche Ltd.
 - 8.3.8. Merck & Co., Inc.
 - 8.3.9. Sanofi S.A.
 - 8.3.10. AbbVie Inc.
 - 8.3.11. AstraZeneca
 - 8.3.12. Bristol-Myers Squibb Company
 - 8.3.13. Eli Lilly and Company
 - 8.3.14. Teva Pharmaceutical Industries Ltd.
 - 8.3.15. Dr. Reddy's Laboratories Ltd.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Genitourinary Drugs Market Size study, by Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), by Product (Hormonal Therapy, Gynecological), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GA8007E67409EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA8007E67409EN.html>